Stay updated on Pembrolizumab for Rare Tumors Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab for Rare Tumors Clinical Trial page.

Latest updates to the Pembrolizumab for Rare Tumors Clinical Trial page
- Check6 days agoChange DetectedThe page now displays Revision: v3.6.6 instead of Revision: v3.6.5, indicating a software update. The study content and layout remain unchanged.SummaryDifference0.0%

- Check13 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedRevision tag updated from v3.6.4 to v3.6.5, indicating a new build or patch of the site or documentation rather than a change to study details.SummaryDifference0.0%

- Check41 days agoChange DetectedThe revision tag was updated from v3.6.3 to v3.6.4. This appears to be a minor software update with no evident changes to content or user-facing features in the provided context.SummaryDifference0.0%

- Check48 days agoChange DetectedThe page's update dates were refreshed in July 2026, replacing earlier January 2026 timestamps. This reflects routine maintenance to keep the study record's metadata current.SummaryDifference0.2%

- Check63 days agoChange DetectedThe page now displays a new revision tag, Revision: v3.6.3, replacing the previous v3.6.2. This indicates a new build of the page content without changing the study details themselves.SummaryDifference0.0%

- Check70 days agoChange DetectedA new publication citation by Derbala et al. was added to the study's Publications, documenting AI-guided analysis predicting pembrolizumab response in rare tumors. The page revision was updated to v3.6.2, replacing the previous v3.6.0.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab for Rare Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for Rare Tumors Clinical Trial page.